Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Summary

This phase II trial studies how well chemotherapy based on positron emission tomography (PET) scan works in treating patients with stage I or stage II Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started. Comparing results of diagnostic procedures, such as PET scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

Conditions

• Lymphoma

Interventions

BIOLOGICAL

Bleomycin Sulfate

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Procarbazine Hydrochloride

Given PO

DRUG

Vinblastine Sulfate

Given IV

DRUG

Dacarbazine

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Etoposide phosphate

Given IV

DRUG

prednisone

Given PO

DRUG

Radiation Therapy

Undergo radiation therapy

RADIATION

Fludeoxyglucose F-18

Undergo FDG PET/CT

PROCEDURE

computed tomography

Undergo FDG PET/CT

PROCEDURE

Positron Emission Tomography

Undergo FDG PET/CT

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Alliance for Clinical Trials in Oncology

  lead OTHER

Principal Investigators

• David J. Straus, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2010-05-31

Primary Completion

2016-02-29

Completion

2018-01-31

Countries

• United States

Study Locations